Novartis’ Hepatitis C Drug Alisporivir Returns To Clinical Testing Minus Interferon
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase II trial of alisporivir plus ribavirin began after FDA modified its partial clinical hold; previous regimen included peg-interferon.
You may also be interested in...
Achillion Readies A Nuc Combo As Acquisition Speculation Swirls
The biotech can move forward with an HCV combo that includes its Phase I nuc and its protease inhibitor now that FDA has partially lifted the hold on the drug.
Achillion Readies A Nuc Combo As Acquisition Speculation Swirls
The biotech can move forward with an HCV combo that includes its Phase I nuc and its protease inhibitor now that FDA has partially lifted the hold on the drug.
Novartis Boosts HCV Portfolio With First-in-Class Debiopharm Compound
Hepatitis C sector heats up as Novartis gains rights to Debiopharm's leading cyclophilin inhibitor